WellDoc’s digital diabetes management therapeutic BlueStar will now be available on the Solera network as a diabetes management option.
Phoenix, Arizona-based Solera Health, a platform which offers a marketplace for chronic disease management programs, and digital therapeutic maker WellDoc announced the partnership today, and said that the partnership aligns both companies' goals to improve the...
Correction: A previous version of this story mistated the projected timeline for the combined product. It is Q1 this year, not Q1 next year.
WellDoc and Voluntis, two companies with FDA-cleared, clinically validated platforms aimed at the management of Type 2 diabetes, have signed a commercial agreement to combine their technologies and offer joint products in the future.
“My thought is that a...
An analysis contracted by WellDoc found that the company’s digital therapeutic for Type 2 diabetes management could lead to an average savings of more than $250 per patient per month.
“The cost of a well-controlled diabetes patient will typically range in the $13,000 range [to] $20,000 annually. When you contrast that with the cost of a patient that doesn’t have diabetes, that number is typically...
A group of health startups in the burgeoning digital therapeutics space have joined together to create a new industry association, the Digital Therapeutics Alliance (DTA).
“Digital therapeutics are re-writing our definition of medicine,” Akili Interactive CEO Eddie Martucci said in a statement. “It’s critical that industry, academia, government, and the medical community work together in the...
AmalgamRx, a newly unstealthed company founded by WellDoc founders Ryan Sysko and Dr. Suzanne Clough, has received FDA clearance for iSage, an insulin titration algorithm.
“One of the big challenges with insulin is that it’s scary for patients, they don’t necessarily want to go on it,” Sysko told MobiHealthNews. “So we wanted to find a way to help them optimize their insulin regimen and get to...
Baltimore, Maryland-based WellDoc, which makes a digital platform for chronic disease management, is teaming up with consumer electronics giant Samsung to offer an integrated tool for people living with diabetes.
BlueStarC will be available directly to consumers under Samsung’s newly launched mobile health app Samsung Health (formerly known as S Health). The diabetes management app is the third...
In the first quarter of 2017, we tracked seven digital health-related FDA clearances. While the list isn’t long, it’s varied and relatively novel – from app and device integrations for diabetes treatment to a vest that maps cardiac rhythms. The beginning of this year also rang in some big changes, as the Trump Administration took root and nominated Dr. Scott Gottlieb as FDA deputy commissioner....
About the author: Naomi Fried, PhD (@NaomiFried), is the CEO of Health Innovation Strategies, which provides digital health strategy and innovation infrastructure consulting to healthcare stakeholders including pharma companies and providers. Her previous positions include the first Chief Innovation Officer at Boston Children’s Hospital, Biogen’s VP of Innovation and External Partnerships, and VP...
The US Food and Drug Administration has given the green light for a non-prescription version of BlueStar, WellDoc’s mobile diabetes management platform.
Through this 510(k) class II clearance, WellDoc will now offer BlueStar and BlueStar Rx, allowing the company to offer the product through more channels. Both versions analyze diabetes data entered by the patient, comparing past data trends to...
WellDoc announced today a partnership with the American Association of Diabetes Educators (AADE), a professional membership organization of over 14,000 diabetes educators. WellDoc will incorporate educational content from AADE into its FDA-cleared, reimburseable BlueStar system for diabetes management.
"We were able to build a curriculum that will be able to be delivered in a contextually guided...
.jpeg?itok=HF3iI7dj "Person answering their front door and getting a delivery from another person")
